10/19/2005 5:11:27 PM
International Wex Technologies Inc. (TSX:WXI) (the "Company") is pleased to announce that the Tectin(TM) Phase II clinical trial in China has commenced to demonstrate the analgesic efficacy of Tectin(TM) in patients with chronic cancer pain. This is an efficacy trial in which an initial phase of escalating dose to the effective dose (Part I) is followed by a controlled phase (Part II). The total participants for Part I and Part II are approximately 300 patients, and will involve up to 8 SFDA (State Food and Drug Administration) authorized centers across China.
comments powered by